Biomarkers of depression

被引：13

作者：

Caruncho, Hector J. ^{[1
]}

Rivera-Baltanas, Tania ^{[1
]}

机构：

[1] Univ Santiago de Compostela, Dept Biol Celular, Grp Invest BIOFARMA, E-15782 Santiago De Compostela, A Coruna, Spain

来源：

REVISTA DE NEUROLOGIA | 2010年 / 50卷 / 08期

关键词：

Antidepressants; BDNF; Cortisol; Serotonin transporter; SEROTONIN TRANSPORTER GENE; NEUROTROPHIC FACTOR LEVELS; STRESSFUL LIFE EVENTS; MAJOR DEPRESSION; ANTIDEPRESSANT; RECEPTORS; BIPOLAR; PHARMACOGENETICS; INTERLEUKIN-6; POLYMORPHISM;

D O I：

10.33588/rn.5008.2010177

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction. The delay in the actions of antidepressants as well as the percentage of patients that do not respond to antidepressant treatment, give rise to a keen interest in the development of biomarkers of therapeutic efficacy in depression, but it is also of importance to work towards the development of biomarkers of vulnerability, diagnosis and prognosis of this disorder. Aims. To analyze what is known of the main genetic, molecular and biochemical biomarkers of depression already validated, and to discuss the present and future of this research field. Development. Among the most repeatedly validated biomarkers of depression are the decrease in serotonin transporter binding in platelets and lymphocytes, hypercortisolemia, hypocholesteremia, decrease in brain-derived neurotrophic factor, decrease in CREB phosphorylation, and an increase in interleukin 6. Conclusion. Some biomarkers related to the pharmacogenetics of antidepressants are already a reality, now the next step will be to develop biomarkers of pathophysiological processes that correlate with important clinical aspects of depression.

引用

页码：470 / 476

页数：7

共 58 条

[1]

ALONSOFERNANDEZ F, 1993, ANN MED-PSYCHOL, V151, P23

[2] Prediction of treatment response in geriatric depression from baseline folate level: Interaction with an SSRI or a tricyclic antidepressant [J].